Business Description
Regenxbio Inc
NAICS : 325412
SIC : 2836
Compare
Compare
Traded in other countries / regions
RB0.GermanyRGNX.USA IPO Date
2015-09-17Description
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.85 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.39 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.43 | |||||
| Beneish M-Score | -1.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 39.6 | |||||
| 3-Year EBITDA Growth Rate | -32 | |||||
| 3-Year EPS without NRI Growth Rate | -36.1 | |||||
| 3-Year FCF Growth Rate | -19.3 | |||||
| 3-Year Book Growth Rate | -0.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.43 | |||||
| 9-Day RSI | 37.24 | |||||
| 14-Day RSI | 39.81 | |||||
| 6-1 Month Momentum % | -5.07 | |||||
| 12-1 Month Momentum % | -27.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.19 | |||||
| Quick Ratio | 3.19 | |||||
| Cash Ratio | 2.8 | |||||
| Days Sales Outstanding | 3.41 | |||||
| Days Payable | 141.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.4 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.61 | |||||
| Operating Margin % | -233.2 | |||||
| Net Margin % | -248.68 | |||||
| ROE % | -44.29 | |||||
| ROA % | -29.14 | |||||
| ROIC % | -47.32 | |||||
| ROC (Joel Greenblatt) % | -129.38 | |||||
| ROCE % | -30.68 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.42 | |||||
| PB Ratio | 1.66 | |||||
| Price-to-Tangible-Book | 1.66 | |||||
| EV-to-EBIT | -2.3 | |||||
| EV-to-Forward-EBIT | -22.35 | |||||
| EV-to-EBITDA | -2.42 | |||||
| EV-to-Forward-EBITDA | -56.03 | |||||
| EV-to-Revenue | 5.24 | |||||
| EV-to-Forward-Revenue | 2.76 | |||||
| EV-to-FCF | -2.51 | |||||
| Price-to-Net-Current-Asset-Value | 8.7 | |||||
| Price-to-Net-Cash | 18.04 | |||||
| Earnings Yield (Greenblatt) % | -43.48 |
How Regenxbio Inc (RGNX) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RGNX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 112.724 | ||
| EPS (TTM) ($) | -6.5 | ||
| Beta | 0.81 | ||
| Volatility % | 56.21 | ||
| 14-Day RSI | 39.81 | ||
| 14-Day ATR ($) | 1.169434 | ||
| 20-Day SMA ($) | 21.726 | ||
| 12-1 Month Momentum % | -27.38 | ||
| 52-Week Range ($) | 18.69 - 35.73 | ||
| Shares Outstanding (Mil) | 43.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regenxbio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regenxbio Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Regenxbio Inc Frequently Asked Questions
What is Regenxbio Inc(RGNX)'s stock price today?
The current price of RGNX is $19.76. The 52 week high of RGNX is $35.73 and 52 week low is $18.69.
When is next earnings date of Regenxbio Inc(RGNX)?
The next earnings date of Regenxbio Inc(RGNX) is 2023-05-04 Est..
Does Regenxbio Inc(RGNX) pay dividends? If so, how much?
Regenxbio Inc(RGNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
